Recent Buy: Gilead Sciences, Inc.

As anticipated for the second quarter, I initiated a new position on Gilead Sciences, Inc. with a purchase of 25 shares bought for 60,53 USD per share. This complements the other pharmaceuticals (AbbVie and Pfizer) and a bit more riskier one. Company financials are not ideal (debt and all) but then again valuation seems to be reflecting it quite nicely. Then again virus focused company is quite nice addition considering how to company is positioned for the ongoing decade. I’m not sure if I will build a full position with any of these companies. Instead I might just handle all of them as a basket of pharmaceuticals filling that position in the portfolio. Might even eventually add few additional ones but let’s see.

Gilead Sciences, Inc. Investor Relations